Clinical Trial Search

Primary: Change From Baseline in Mean Unified Huntington's Disease (HD) Rating Scale Total Maximal Chorea (UHDRS TMC) Score — -2.4 score on a scale — p=0.27

Primary: Tinetti Mobility Test Score — 19.91; 17.09 Total Tinetti Mobility Test Score (TMT)

Primary: Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. — -4.60; -1.44…

Primary: Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment. — 0.4; -0.8; -1.4…

Primary: Change From Baseline (Average of Screening and Day 0) in the Average TMC Scores From Weeks 9 & 12 — -4.42; -1.93 Units on a scale — p=<0.0001

Primary: Change in Total Maximal Chorea (TMC) Score of the UHDRS® for Subjects Not Taking Neuroleptics During the Trial (mITT - N=122) — -2.19; -2.42; -3.46 units on a scale…

Primary: Number of Patients With at Least One Adverse Event — 119 Participants

Primary: Quantitative Electroencephalography Absolute Delta Power. — 43.45; 10.11 microvolts squared — p=<0.0000001

Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…

Primary: Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (1TCM Model) — 44.5; 39.3; 62.7; 38.6 mL/cm^3

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, Drug-Related TEAEs, and TEAEs Leading to Withdrawal During Entire…

Primary: 30-day Hospital Readmission — 11; 9 30-day hospital readmissions

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 18; 14; 1; 1 participants

Primary: Change in the Hopkins Verbal Learning Test - Revised for Delayed Recall (HVLT-R-delayed Recall)

Primary: Gait Parameters — 1.289; 1.292 meters per second